Pharma Q2 Preview: Cipla to see steady qtr; higher profit growth for DRL

Cipla could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on account of lower Albuterol Sulphate sales. Revenue for the quarter is likely to grow at 13% year-on-year (YoY), according to an average estimate of three brokerages, and net profit for […]

P-notes investment continues to swell for seventh month on robust macros

The latest data includes the value of p-note investments in Indian equity, debt, and hybrid securities. Participatory notes (P-notes) are issued by registered Foreign Portfolio Investors (FPIs) to overseas investors who wish to be part of the Indian stock market without registering themselves directly.